Beijing, July 12, 2024 (GLOBE NEWSWIRE) — Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the pricing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for […]
Category Archives: Pr Newswire
Pr Newswire
Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
12
Jul
Jul
LOUISVILLE, Ky., July 12, 2024 (GLOBE NEWSWIRE) — Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Geron Corporation for Rytelo™ (imetelstat) as a first in class oral, oligonucleotide telomerase inhibitor, approved for the treatment of adult patients with low to intermediate risk myelodysplastic syndromes (MDS) with transfusion dependent (TD) […]
Pr Newswire
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
12
Jul
Jul
– Findings reported today in the journal Lancet Infectious Diseases– Study shows synergistic immunological response generated by M2SR and Fluzone High Dose vaccine when used in combination in the highly vulnerable 65-85 years old population – Results suggest approach could be used for vaccination against future influenza pandemics such as H5N1 MADISON, Wis., July 12, 2024 […]
Pr Newswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
12
Jul
Jul
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. The poster will report results of an ongoing phase 1b/2 […]
SINGAPORE, July 12, 2024 /PRNewswire/ — Almost 1,000 new condo enthusiasts thronged Suntec Convention Centre for an industry analysis of over 80 of Singapore’s past and upcoming new launch condominiums. A first-of-its-kind cross-industry collaboration between PropertyLimBrothers Media, personal finance platform Seedly, and event partner Unearthed Productions, the New Launch Convention 2024 was a timely showcase […]
BEIJING, July 12, 2024 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD), an AI-powered platform providing financial and lifestyle services in China, recently released its first ESG report. The report underscores Yiren Digital’s mission of “Better Lives Through Digital Innovation,” highlighting its commitment to environmental sustainability and social responsibility. Here are the highlights at a glance. […]
TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ — Senhwa Biosciences’ new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been selected for presentation at the 2024 European Society for Medical Oncology (ESMO) congress. This achievement is a significant […]
Flagship programme doubles down on five aspects of platform work that foodpanda’s delivery partners value KUALA LUMPUR, Malaysia and BANGKOK, July 12, 2024 /PRNewswire/ — Leading food and grocery delivery platform foodpanda is doubling down on its commitment to its delivery partners with ‘panda hearts’, its flagship programme aimed at uplifting and supporting delivery partners in five […]
HONG KONG, July 12, 2024 /PRNewswire/ — Highway Holdings Limited (Nasdaq: HIHO) (the “Company” or “Highway Holdings”) today announced it has restated its unaudited quarterly financial statements for the three and nine months ended December 31, 2023, which were released in an earnings press release on February 1, 2024. The decision to restate the financial […]
Pr Newswire
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
12
Jul
Jul
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment Durability […]